CureVac' (CVAC) CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19

Go back to CureVac' (CVAC) CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19

CureVac N.V. (CVAC) sinks 51% after-hours after its COVID-19 vaccine only showed 47% efficacy

June 16, 2021 4:50 PM EDT

CureVac N.V. (NASDAQ: CVAC) sinks 51% after-hours after its COVID-19 vaccine only showed 47% efficacy.

... More